OrbiMed

Neurogastrx, Inc. is a venture-stage biopharmaceutical company focused on developing innovative therapies for gastrointestinal disorders. Established in 2017 and located in Campbell, California, the company aims to address the unmet medical needs associated with functional and motility disorders of the gastrointestinal tract. One of its key products, NG101, is designed to enhance gastric motility while also possessing antiemetic properties. Neurogastrx's specialty therapies target the enteric nervous system, addressing issues related to gut contractions, sensation, and the brain-gut axis, ultimately striving to alleviate the burden of these disorders on patients and the healthcare system.

Sparrow Pharmaceuticals, founded in 2013 and based in Portland, Oregon, focuses on developing targeted therapies for conditions related to corticosteroid excess. The company aims to provide innovative treatment options for disorders linked to elevated levels of cortisol, which can arise from tumors or prolonged use of corticosteroid medications like prednisone. By addressing serious issues associated with hypercortisolism, Sparrow Pharmaceuticals seeks to enhance the management of autoimmune and inflammatory conditions, ultimately improving patient care and outcomes in this challenging medical area.

VIVUS, Inc. is a specialty pharmaceutical company based in Campbell, California, focused on the development and commercialization of therapeutic products for obesity, diabetes, sleep apnea, and sexual health. The company offers Qsymia, a treatment for obesity designed to assist adults with a body mass index of 30 or greater, or 27 or greater with weight-related health issues, in managing their weight alongside a reduced-calorie diet and increased physical activity. VIVUS also provides PANCREAZE, which addresses exocrine pancreatic insufficiency, and STENDRA/SPEDRA, an oral medication for erectile dysfunction. Additionally, the company is advancing its pipeline with ongoing clinical studies for Qsymia to treat conditions such as obstructive sleep apnea and diabetes, as well as VI-0106 for pulmonary arterial hypertension. VIVUS has established collaborative agreements with several pharmaceutical firms to enhance its research and development efforts. Founded in 1991, VIVUS continues to focus on innovative solutions that address significant health issues facing patients.

KANDY THERAPEUTICS LIMITED develops non-hormonal treatment for multiple symptoms of the menopause including hot flashes and night time awakening. The company offers NT-814, a drug for common, chronic debilitating female sex-hormone related treatment. It provides non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms, enabling patients to receive treatment, and reduce symptoms of hormone related conditions. The company was founded in 2017 and is based in Stevenage, United Kingdom. KANDY THERAPEUTICS LIMITED operates as a subsidiary of Bayer Aktiengesellschaft.

Sublimity Therapeutics (formerly Sigmoid Pharma), is a specialty pharma company with offices in Dublin, Ireland, and Solana Beach, California. Sublimity’s goal is to identify and create meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases. Sublimity’s priority focus is on its lead product, STI-0529, for treatment of moderate to severe ulcerative colitis.

Neurogastrx, Inc. is a venture-stage biopharmaceutical company focused on developing innovative therapies for gastrointestinal disorders. Established in 2017 and located in Campbell, California, the company aims to address the unmet medical needs associated with functional and motility disorders of the gastrointestinal tract. One of its key products, NG101, is designed to enhance gastric motility while also possessing antiemetic properties. Neurogastrx's specialty therapies target the enteric nervous system, addressing issues related to gut contractions, sensation, and the brain-gut axis, ultimately striving to alleviate the burden of these disorders on patients and the healthcare system.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions in infants. The company’s primary clinical programs include NTRA-2112, which addresses intestinal malabsorption in preterm infants by improving enteral nutrition tolerance, enhancing growth velocity, and reducing the length of stay in neonatal intensive care units. Another key product, NTRA-9620, targets short bowel syndrome by promoting bowel adaptation after surgical resection and minimizing reliance on parenteral nutrition. Nutrinia’s innovative approach includes oral formulations of insulin to support gut rehabilitation in infants. Founded in 2003 and based in Ramat-Gan, Israel, Nutrinia is dedicated to improving health outcomes for vulnerable populations.

Manufacturer of healthcare formulations designed for a range of medical applications. The company manufactures a comprehensive range of generic pharmaceutical formulations such as allopathic formulations, intravenous infusions, ophthalmics, and sterilized water for injections and other similar products in a variety of forms, in the most sterile and highest-quality packaging, enabling healthcare providers and the medical community to economically meet medical supply needs.

Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions in infants. The company’s primary clinical programs include NTRA-2112, which addresses intestinal malabsorption in preterm infants by improving enteral nutrition tolerance, enhancing growth velocity, and reducing the length of stay in neonatal intensive care units. Another key product, NTRA-9620, targets short bowel syndrome by promoting bowel adaptation after surgical resection and minimizing reliance on parenteral nutrition. Nutrinia’s innovative approach includes oral formulations of insulin to support gut rehabilitation in infants. Founded in 2003 and based in Ramat-Gan, Israel, Nutrinia is dedicated to improving health outcomes for vulnerable populations.

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, that specializes in developing and commercializing innovative therapies for iron deficiency, nephrology, and cardio-renal conditions. The company's primary product is VELTASSA, a potassium binder used for treating hyperkalemia. Relypsa focuses on creating novel non-absorbed polymeric drugs aimed at addressing significant medical needs in cardiovascular and renal diseases. Established in 2007, Relypsa is committed to advancing its proprietary polymer platform to discover and develop additional therapeutic candidates. As of August 2016, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, that specializes in developing and commercializing innovative therapies for iron deficiency, nephrology, and cardio-renal conditions. The company's primary product is VELTASSA, a potassium binder used for treating hyperkalemia. Relypsa focuses on creating novel non-absorbed polymeric drugs aimed at addressing significant medical needs in cardiovascular and renal diseases. Established in 2007, Relypsa is committed to advancing its proprietary polymer platform to discover and develop additional therapeutic candidates. As of August 2016, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, that specializes in developing and commercializing innovative therapies for iron deficiency, nephrology, and cardio-renal conditions. The company's primary product is VELTASSA, a potassium binder used for treating hyperkalemia. Relypsa focuses on creating novel non-absorbed polymeric drugs aimed at addressing significant medical needs in cardiovascular and renal diseases. Established in 2007, Relypsa is committed to advancing its proprietary polymer platform to discover and develop additional therapeutic candidates. As of August 2016, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, that specializes in developing and commercializing innovative therapies for iron deficiency, nephrology, and cardio-renal conditions. The company's primary product is VELTASSA, a potassium binder used for treating hyperkalemia. Relypsa focuses on creating novel non-absorbed polymeric drugs aimed at addressing significant medical needs in cardiovascular and renal diseases. Established in 2007, Relypsa is committed to advancing its proprietary polymer platform to discover and develop additional therapeutic candidates. As of August 2016, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

Eddingpharm, established in 2001, is a pharmaceutical company focused on supplying high-quality patented and branded drugs to the Chinese healthcare market. The company aims to bridge the gap between Chinese patients and global medicines by acquiring classic branded medications from multinational corporations and introducing innovative patented drugs. Eddingpharm has rapidly expanded its operations across China, deploying nearly 1,000 professional representatives in 30 provinces, with access to over 19,000 hospitals and 20,000 pharmacies. Its collaborations with multinational pharmaceutical companies and leading research institutions have enriched its product portfolio, particularly in therapy areas such as oncology, cardiovascular, respiratory, and renal diseases. A notable product in its line is Vascepa®, a prescription medication that lowers triglyceride levels without raising LDL cholesterol. Eddingpharm has been granted development and commercialization rights for Vascepa® in mainland China, Hong Kong, Macau, and Taiwan, and is currently conducting clinical trials to support its regulatory registrations. The company's commitment to professionalism, excellence, responsibility, and persistence underpins its mission to enhance treatment options for patients in China.

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, that specializes in developing and commercializing innovative therapies for iron deficiency, nephrology, and cardio-renal conditions. The company's primary product is VELTASSA, a potassium binder used for treating hyperkalemia. Relypsa focuses on creating novel non-absorbed polymeric drugs aimed at addressing significant medical needs in cardiovascular and renal diseases. Established in 2007, Relypsa is committed to advancing its proprietary polymer platform to discover and develop additional therapeutic candidates. As of August 2016, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

Amarin Corporation plc is a pharmaceutical company dedicated to developing and commercializing therapeutics for cardiovascular diseases in the United States. Its primary product, Vascepa, is a prescription omega-3 fatty acid capsule designed to reduce triglyceride levels in adults with severe hypertriglyceridemia. The company is also conducting research on the REDUCE-IT study, which targets patients with high triglyceride levels who are undergoing statin therapy. Amarin markets its products primarily to wholesalers and specialty pharmacy providers, utilizing a direct sales force. The company has partnered with Mochida Pharmaceutical Co., Ltd. to further develop and commercialize products based on the active ingredient in Vascepa, eicosapentaenoic acid. Founded in 1989 and headquartered in Dublin, Ireland, Amarin has a research and development facility in Mystic, Connecticut, and focuses on lipid science to enhance cardiovascular disease management.

Gelesis, Inc. is a biotechnology company focused on developing therapies for gastrointestinal-related chronic diseases, particularly obesity and type 2 diabetes. Utilizing a mechanobiology technology platform, Gelesis creates innovative products aimed at weight management. Its lead product, Gelesis100, is an orally administered smart pill composed of hydrogel particles that expand in the gastrointestinal tract, promoting a feeling of fullness and aiding in calorie reduction. This product is designed to be safe, having materials recognized as safe by regulatory authorities. In addition to Gelesis100, the company has a pipeline of potential therapies targeting conditions such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic idiopathic constipation. Founded in 2006, Gelesis is based in Boston, Massachusetts.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The company’s extensive expertise in product development has been built over the past 20 years: initially as a stand alone development organization, then as a U.S. subsidiary of Shire plc and, upon its acquisition of substantially all the assets of Shire Laboratories Inc. in late 2005, as Supernus Pharmaceuticals. The company is developing several product candidates in neurology and psychiatry to address large market opportunities in epilepsy, ADHD and depression. In addition to its two ADHD product candidates, Supernus is developing two late stage epilepsy product candidates, SPN-538 (extended release topiramate), and Epliga® (extended release oxcarbazepine).